1800-272-662
Shopping Cart 0
countryflagAU
Login

Relay Therapeutics Inc

Healthcare US RLAY

10.36USD
-0.19(1.80%)

Last update at 2026-03-13T20:00:00Z

Day Range

10.3011.49
LowHigh

52 Week Range

5.7013.32
LowHigh

Fundamentals

  • Previous Close 10.55
  • Market Cap898.66M
  • Volume1630973
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-363.96998M
  • Revenue TTM35.33M
  • Revenue Per Share TTM0.28
  • Gross Profit TTM 1.38M
  • Diluted EPS TTM-2.61

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -290.50900M -363.87200M -52.41200M -75.30500M -48.78500M
Minority interest - - - - -
Net income -254.25900M -496.80800M -49.01200M -66.50400M -48.78500M
Selling general administrative 65.98M 57.39M 38.59M 13.74M 8.86M
Selling and marketing expenses - - - - -
Gross profit 1.38M 3.03M 82.65M - -
Reconciled depreciation 4.13M 3.92M 3.55M 2.85M 2.15M
Ebit -299.27500M -364.69800M -55.79600M -84.04800M -48.78500M
Ebitda -322.62900M -89.31600M -52.24700M -81.20300M -46.63100M
Depreciation and amortization -23.35400M 275.38M 3.55M 2.85M 2.15M
Non operating income net other 8.79M 0.83M 3.12M - -
Operating income -299.27500M -364.69800M -55.79600M -84.04800M -49.88900M
Other operating expenses 312.33M 230.04M 138.45M 84.05M 49.89M
Interest expense 8.77M 0.83M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income 8.79M 0.83M 3.40M 8.80M 1.11M
Net interest income 8.79M 0.83M 3.40M 8.80M 1.11M
Extraordinary items - - - - -
Non recurring - 123.00M - - -
Other items - - - - -
Income tax expense -36.25000M 132.94M -3.40000M -8.80100M 1.10M
Total revenue 1.38M 3.03M 82.65M 0.00000M 0.00000M
Total operating expenses 312.33M 230.04M 138.45M 84.05M 49.89M
Cost of revenue - - - - -
Total other income expense net 8.77M 0.83M 3.38M 8.74M 1.10M
Discontinued operations - - - - -
Net income from continuing ops -290.50900M -363.87200M -52.41200M -75.30500M -48.78500M
Net income applicable to common shares -290.50900M -363.87200M -230.20100M -75.30500M -48.78500M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 843.98M 1099.77M 1008.44M 799.83M 393.07M
Intangible assets 2.30M 2.30M 2.30M - -
Earning assets - - - - -
Other current assets 3.31M 3.26M 695.72M 247.45M 4.72M
Total liab 91.98M 149.55M 110.64M 36.54M 573.51M
Total stockholder equity 752.00M 950.22M 897.81M 763.29M -180.43800M
Deferred long term liab - - - - -
Other current liab 1.20M 48.85M 13.95M 0.20M 0.33M
Common stock 0.13M 0.12M 0.11M 0.09M 0.00400M
Capital stock 0.13M 0.12M 0.11M 0.09M 0.00400M
Retained earnings -1400.58200M -1058.60900M -768.10000M -404.22800M -189.48200M
Other liab - 32.38M 65.26M 0.00300M 0.16M
Good will - - - - -
Other assets - 2.58M 2.58M 0.02M 0.88M
Cash 143.74M 998.92M 958.07M 447.65M 41.95M
Cash and equivalents - - - - -
Total current liabilities 30.27M 63.71M 24.32M 13.63M 11.99M
Current deferred revenue 14.89M - 0.25M 5.56M 3.41M
Net debt -90.27000M -941.17500M -935.17300M -423.22400M -17.12200M
Short term debt 4.96M 4.28M 1.84M 1.52M 1.25M
Short long term debt - - - - -
Short long term debt total 53.47M 57.74M 22.90M 24.42M 24.83M
Other stockholder equity 2152.65M 2019.13M 1666.89M 367.54M 8.71M
Property plant equipment - 11.63M 6.54M 28.83M 31.65M
Total current assets 770.10M 1019.50M 976.24M 770.10M 360.54M
Long term investments - - - - -
Net tangible assets - 947.92M 895.51M 763.29M -180.43800M
Short term investments 606.35M 847.12M 677.95M 230.41M 313.86M
Net receivables 0.00000M 5.22M 4.94M 82.65M -
Long term debt - - - - -
Inventory - 12.11M -682.49100M -238.06900M -
Accounts payable 9.21M 10.58M 8.28M 6.35M 6.99M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.19600M -10.42000M -1.08800M 0.06M 0.33M
Additional paid in capital - - - - -
Common stock total equity - 0.12M 0.11M 0.09M 0.00400M
Preferred stock total equity - - - - -
Retained earnings total equity - -1058.60900M -768.10000M -404.22800M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.71M 2.58M 2.58M 0.90M 0.88M
Deferred long term asset charges - - - - -
Non current assets total 73.88M 80.27M 32.20M 29.73M 32.53M
Capital lease obligations 53.47M 57.74M 22.90M 24.42M 24.83M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -188.74500M -450.74200M 81.67M -319.02400M -1.68000M
Change to liabilities 21.80M 21.93M -0.41000M 3.00M 1.23M
Total cashflows from investing activities -188.74500M -479.51100M 81.67M -319.02400M -1.68000M
Net borrowings - - -2.50700M - -
Total cash from financing activities 289.91M 388.09M 426.51M 5.61M 394.97M
Change to operating activities 9.78M 18.62M -2.10600M 1.31M -1.63200M
Net income -290.50900M -363.87200M -52.41200M -75.30500M -48.78500M
Change in cash -128.32500M -165.82700M 405.69M -379.55100M 349.16M
Begin period cash flow 282.70M 448.52M 42.83M 422.38M 73.23M
End period cash flow 154.37M 282.70M 448.52M 42.83M 422.38M
Total cash from operating activities -229.49000M -74.40600M -102.48900M -66.13300M -44.13500M
Issuance of capital stock 284.74M 382.21M 427.80M 4.99M 394.25M
Depreciation 4.13M 3.92M 3.55M 2.85M 2.15M
Other cashflows from investing activities - -25.29800M - -311.02200M 0.00700M
Dividends paid - - - - -
Change to inventory - 21.46M -10.33100M - -
Change to account receivables 0.10M 74.68M -75.00000M -82.65400M -82.65400M
Sale purchase of stock 1.69M 5.88M 429.02M 5.61M 394.25M
Other cashflows from financing activities 5.17M 5.88M -1.29100M 4.99M 394.97M
Change to netincome 56.14M 51.29M 31.54M 2.02M 2.90M
Capital expenditures 9.06M 3.47M 1.93M 8.00M 1.69M
Change receivables 0.10M 74.68M -75.00000M - -
Cash flows other operating -22.32500M 135.59M -11.77000M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -128.32500M -165.82700M 405.69M - -
Change in working capital 11.25M 97.34M -85.17000M 4.31M -0.40000M
Stock based compensation 56.14M 48.45M 31.96M 4.46M 2.89M
Other non cash items -10.49500M 137.69M -0.41600M -2.43900M 0.00900M
Free cash flow -238.55200M -77.87700M -104.42000M -74.13500M -45.82200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RLAY
Relay Therapeutics Inc		 -0.19 1.80% 10.36 - - 36.10 1.23 8.86 -0.6046
NVO
Novo Nordisk A/S		 -0.06 0.16% 37.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.315 0.82% 38.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -8.79 1.84% 469.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -0.84 0.11% 745.77 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Relay Therapeutics Inc

399 Binney Street, Cambridge, MA, United States, 02139

Key Executives

Name Title Year Born
Mr. Alexis A. Borisy A.M. Co-Founder & Independent Chairman 1972
Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS CEO, Pres & Director 1974
Dr. Mark Murcko Ph.D. Co-Founder & Director 1960
Mr. Thomas Catinazzo Chief Financial Officer 1977
Mr. Andy Porter Chief Admin. Officer NA
Mr. Brian R. Adams J.D. Chief Legal Officer & Sec. 1974
Dr. Donald A. Bergstrom M.D., Ph.D. Pres of R&D 1972
Mr. Peter Rahmer Sr. VP of Corp. Affairs & Investor Relations NA
Dr. Deborah Palestrant Ph.D. VP of Corp. Devel. & Strategy NA
Mr. Jim Watters Ph.D. Sr. VP & Head of Late Research NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.